The FDA approved dupilumab for the treatment of patients 12 years and older with chronic spontaneous urticaria who remain ...

Resubmission of the supplemental biologics license application provided more data on improvement in hives and itching in ...

Chronic spontaneous urticaria is chronic inflammatory skin disease driven in part by type 2 inflammation, which causes sudden ...

Marking the first approval in over a decade for this challenging condition, the FDA has approved dupilumab (Dupixent) to treat chronic spontaneous urticaria in patients 12 years and older whose hives ...

Background: Chronic spontaneous urticaria (CSU) is a clinical condition that affects patients quality of life. Omalizumab is preferred in antihistamines resistant CSU cases. Urticaria activity score-7 ...

Evidence of type 2 inflammation (sinus tissue eosinophil count ≥10 eosinophils per high-powered field or peripheral blood eosinophils ≥150 cells/ul or total IgE ≥100 international units/ml)” – “Need ...

The cardiovascular safety of oral semaglutide, a glucagon-like peptide 1 receptor agonist, has been established in persons with type 2 diabetes and high cardiovascular risk. An assessment of the ...

Skin and mucosal involvement was present in 21 patients (84%) with recurrent episodes of maculopapular skin rash, urticaria and minor oral aphthosis. Giant oral ulcers were reported rarely (2 patients ...

HealthDay News — For patients with symptomatic chronic spontaneous urticaria after treatment with second-generation H 1-antihistamines, administration of the oral, highly selective Bruton’s tyrosine ...